> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Voucher Redeemed on Fabhalta’s Approval
- URL: https://www.fdaweb.com/voucher-redeemed-on-fabhaltas-approval/
- Published: 2024-01-16T12:00:00.000Z
- Updated: 2026-09-14T14:20:24.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5156141

*Federal Register* notice: FDA is announcing the approval of a product that redeemed a material threat medical countermeasure priority review voucher — Novartis’ Fabhalta (iptacopan), indicated as monotherapy for treating adults with paroxysmal nocturnal hemoglobinuria. The agency determined that the drug application, which was approved 12/5/2023, met the voucher redemption criteria. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2024-01-16/pdf/2024-00688.pdf?ref=fdaweb.com).